Clinical trial
Celecoxib in Preventing Skin Cancer
NCT00025051 · National Cancer Institute (NCI), NIH · Withdrawn
Key facts
| NCT number | NCT00025051 |
|---|---|
| Title | Celecoxib in Preventing Skin Cancer |
| Official title | A Phase II, Double-Blind, Placebo-Controlled Clinical Trial To Assess Celecoxib As A Chemopreventive Agent Inhibiting UV-Induced Erythema And Cutaneous Carcinogenesis As Assessed Through Surrogate Biological Markers In Biopsied Skin After Exposure Of Skin In Normal Volunteers Ages 20-60 Years Old… |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-melanomatous Skin Cancer |
| Intervention type | Drug, Procedure |
| Interventions | celecoxib, anti-cytokine therapy, antiangiogenesis therapy, biological therapy, cancer prevention intervention, chemoprevention of cancer, growth factor antagonist therapy |
| Enrollment | 0 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 22, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: